Launch mavacamten
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 16 Nov 2021
- Due
- 31 Dec 2022
- Delivered
- by 28 Apr 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Deliver successful launch of mavacamten over the next year”
What we found
Evidence strength A What the grades mean
The company successfully launched mavacamten (marketed as Camzyos) in April 2022, which is within the one-year timeframe following the November 2021 announcement.
-
A Bristol Myers Squibb Co. 8-K filed 2023-01-09
“Camzyos oHCM” ✓ confirmed on the page
Market reaction: the shares moved -3.4% against the S&P 500 over the three sessions around the disclosure (6 Jan 2023 to 11 Jan 2023). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- mavacamten launch
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Bristol Myers Squibb Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BMY-004297 · Corrections policy